We evaluated 24 Veterans with advanced non-small cell lung cancer treated with pembrolizumab. 41% of patients had durable clinical benefit to therapy. We showed that Veterans with high comorbidity scores responded as well as the general population to immunotherapy. A rise in absolute lymphocyte count may be associated with clinical benefit and warrants further investigation.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kULxaN
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Objective Outpatient parenteral antimicrobial therapy (OPAT) provides opportunities for improved cost savings, but in the UK, implementation...
-
Abstract Purpose Overcoming the flaws of current data management conditions in head and neck oncology could enable integrated informatio...
-
http://orl-agios.blogspot.com/2017/06/the-preclinical-anticancer-effect-of.html Flavonoids present in foods were considered non-absorbable b...
-
Vol.31 No.5 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1k8FKtW via IFTTT
-
Universal newborn hearing screening (UNHS) has become the standard of care in many countries. The aim of this study was to evaluate the resu...
-
Geographic region: Does it matter in cutaneous melanoma of the head and neck? Laryngoscope. 2017 Jun 05;: Authors: Kılıç S, Unsal AA,...
-
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of lichen sclerosus (LS)...
-
Abstract The head-mounted display (HMD) has the potential to improve the quality of ultrasound-guided procedures. The aim of this non-clin...
-
http://ift.tt/2pnwWaQ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου